A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Linking FOXM1 and PD-L1 to CDK4/6 ...

We suggest that future therapeutic strategies targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 represent ...

A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, "Linking FOXM1 and PD-L1 to CDK4/6 ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that we have completed enrollment ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

Detailed price information for Arbutus Biopharma Corp (ABUS-Q) from The Globe and Mail including charting and trades.

By way of two resoundingly consistent votes, members of an FDA advisory committee agreed that PD-1 inhibitors do not have a favorable risk/benefit profile for gastroesophageal cancers with low PD-L1 ...

Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...

The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.

September 30, 2024, Akeso (9926. HK) announced that its internally developed PD-1/CTLA-4 bispecific antibody, cadonilimab, has received approval from the National Medical Products Administration (NMPA ...

Northwestern Medicine scientists have developed a more effective method of delivering a cutting-edge cancer treatment, ...

On September 3, OBX-115, a novel TIL therapy, was granted FDA regenerative medicine advanced therapy (RMAT) designation in ...